Peptide Schedule
Lanreotide (Somatuline Depot)8 residuesCVYWKTCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Lanreotide (Somatuline Depot) Dosage Calculator

MetabolicInjectionFDA Approved~23-30 days half-life

Lanreotide is a synthetic octapeptide analog of somatostatin, marketed as Somatuline Depot.

Normalizes GH and IGF-1 levels in 50-70% of acromegaly patientsSignificantly prolongs progression-free survival in GEP-NETs (CLARINET trial: 53% risk reduction)Reduces pituitary tumor volume by ≥20% in ~63% of patients (PRIMARYS trial)Once-monthly dosing with pre-filled syringe — no reconstitution required

60mcg · Monthly

100500
0.0 units
100 units (1mL)
Concentration
0
mcg/mL
Draw Volume
< 0.001
mL
Syringe Units
< 0.1
units
Doses / Vial
0
doses

Summary: Add 0mL BAC water to your 60mg vial. Draw to < 0.1 units on a U-100 syringe for a 60mcg dose. This vial will last 0 doses.

Cycle Planner

Deep subcutaneous (upper outer quadrant of buttock). Typical beginner frequency: monthly.

Lanreotide (Somatuline Depot) Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~23-30 days (depot formulation)
50%25%12.5%100%75%50%25%0%027d53d80d106d133dTime after injectionDose remaining
After 1 half-life (27d): 50% remainsAfter 2 half-lives (53d): 25% remainsAfter 3 half-lives (80d): 12.5% remains
At a 90mcg dose: 50% = 45mcg remaining after 27d. Recommended frequency: Monthly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Lanreotide (Somatuline Depot) Dosing Protocol

LevelDose / InjectionFrequency
Beginner60mgMonthly
Moderate90mgMonthly
Aggressive120mgMonthly

Note: Lanreotide is administered as a deep subcutaneous injection every 28 days, not weekly. The "Weekly" frequency is used as the closest valid option — actual dosing is once every 4 weeks (q28d). Available as a pre-filled syringe (Somatuline Depot) in 60mg, 90mg, and 120mg strengths. Dose selection depends on GH/IGF-1 levels for acromegaly or tumor grade for GEP-NETs. Do not mix or dilute — inject the full syringe at room temperature into the upper outer quadrant of the buttock.

About Lanreotide (Somatuline Depot)

Lanreotide is a synthetic octapeptide analog of somatostatin, marketed as Somatuline Depot. It binds primarily to somatostatin receptor subtypes 2 (SST2) and 5 (SST5), inhibiting growth hormone (GH) secretion, reducing IGF-1 levels, and exerting antiproliferative effects on neuroendocrine cells. FDA-approved since 2007 for acromegaly and since 2014 for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The depot formulation uses a supersaturated solution that forms a gel deposit at the injection site, providing sustained drug release over 28 days.

Frequently Asked Questions